Illumina, Inc. (ILMN) fair value analysis
Nasdaq · Updated 2026-10-19
ILMN price how computed
Forward Fair Value verdict
OvervaluedILMN is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $278.17
- Sector
- Healthcare
- 12-month range
- $95.03–$293.69
- Market cap
- $42B
- From 52-week high
- -5.3%
- Shares outstanding
- 151M
- Rank in Healthcare by discount to fair value
- #92 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Illumina, Inc. is a company that develops and manufactures DNA sequencing and genetic analysis systems used in research, clinical diagnostics, and other applications. The company operates globally with operations across multiple regions including North America, Europe, and Asia-Pacific.
ILMN currently ranks #92 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $42B
- P/E (trailing)
- 54x
- Revenue (TTM)
- $4.49B
- Net margin
- 18.4%
- EPS (TTM)
- $5.15
- Gross margin
- 66.4%
- Debt / equity
- 0.89
- Revenue growth (3-yr avg)
- 1.2%
- Shares outstanding
- 151M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 54 · neutral
- 50-day average
- $233.92
- 200-day average
- $169.65
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-10-29 (post-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.5%)
2026-03 ▲ beat (+8.5%)
2025-12 ▲ beat (+9.8%)
2025-09 ▲ beat (+14.5%)
2025-06 ▲ beat (+17.8%)
2025-03 ▲ beat (+3.2%)
2024-12 ▼ miss (-6.5%)
2024-09 ▲ beat (+29.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 6 hold · 4 sell (21 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $241
- Target vs last price
- -13.4%
What our data shows for ILMN
- Our model validated 10 trailing price-to-earnings windows for ILMN, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $95.03–$293.69.
- The 14-day relative strength index sits at a neutral 54.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ILMN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ILMN news
TickrTrends' derived news-sentiment signal for ILMN is currently leaning positive, computed from recent coverage.
- Illumina Inc (ILMN) Stock Up 5.6% but GF Value Says Overvalued -- GF Score: 65/100 (gurufocus.com, 2026-10-21)
TickrTrends take: Illumina's recent stock appreciation occurs against a backdrop where TickrTrends identifies the company as overvalued within the Healthcare sector. The disparity between price movement and valuation assessment suggests investors focused on intrinsic value should monitor whether the stock's valuation metrics narrow or whether fundamental business improvements justify current price levels. GF Score of 65 out of 100 indicates middling quality fundamentals, making the overvalued designation particularly relevant for value-conscious investors evaluating entry points. - ILMN Maintained by Canaccord Genuity -- Price Target Raised to $300 (gurufocus.com, 2026-10-19)
TickrTrends take: Canaccord Genuity's raised price target of $300 for ILMN contrasts with TickrTrends' current assessment that the stock is overvalued, suggesting the market may have different expectations about the company's future earnings power or growth trajectory. The maintained rating indicates analyst confidence in ILMN's fundamentals despite the valuation concerns flagged by trend-based metrics, which typically reflects concern about current pricing relative to traditional financial metrics. Investors focused on valuation should monitor whether ILMN's operational performance and earnings growth can justify closing the gap between current trading levels and analyst targets. - Illumina’s (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself? (insidermonkey.com, 2026-10-13)
TickrTrends take: Illumina's sequencing business recovery suggests operational momentum that could support future earnings growth, yet TickrTrends currently classifies the stock as overvalued based on its derived metrics. For valuation-focused investors, the key question is whether the company's operational improvements will justify current pricing or whether the market is pricing in recovery expectations faster than fundamentals warrant. Monitoring the pace at which sequencing revenue converts to operating leverage and free cash flow will be critical to determining if the valuation premium narrows or expands from current levels.
More ILMN news
- Illumina, Inc. (ILMN) -- Driving Innovation in Genomics | Hardman Johnston Q3 2026 (gurufocus.com, 2026-10-11)
- Illumina, Inc. (ILMN) -- Driving Innovation in Genomics | Hardman Johnston Q3 2026 (gurufocus.com, 2026-10-11)
What people are saying
Follow the ILMN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for ILMN showed a shift in momentum this week as the relative strength index moved from overbought territory into neutral zone. The stock remains classified as overvalued according to current valuation metrics within the healthcare sector.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — ILMN's quality grade improved from C to B this week, indicating enhanced fundamental strength in the Healthcare sector stock. Concurrently, the relative strength index shifted from neutral into overbought territory, suggesting upward momentum in price movement. The stock remains classified as overvalued according to current valuation assessment.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ILMN stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ILMN is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is ILMN's TickrTrends verdict?
ILMN's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does ILMN compare to other Healthcare stocks?
ILMN ranks #92 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ILMN overbought or oversold?
ILMN's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ILMN report earnings next?
ILMN's next earnings report is scheduled for 2026-10-29 (post-market), per the published earnings calendar.
Does ILMN usually beat earnings estimates?
Over its last 8 reported quarters ILMN beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ILMN?
Of 21 analysts covering ILMN, 11 rate it a buy, 6 a hold and 4 a sell - buy-leaning, with a consensus price target of $241 (-13.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ILMN vs ALKS · ILMN vs CDNA · ILMN vs CRL · ILMN vs HUM · ILMN vs JNJ